PTC Therapeutics

PTC THERAPEUTICS INC

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

PTCT

Biotech

News

Health Care

General

PTC Therapeutics&#39; Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA applications, all under review.

European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder

Stuttgart,,Germany,-,11-07-2023:,Mobile,Phone,With,Website,Of,Us

PTC Therapeutics presented new Phase 3 data on sepiapterin, showing potential benefits for PKU patients ahead of key regulatory decisions in 2025.

PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July

GE HealthCare

Upgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

GEHC

MSGE

This GE HealthCare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

PTC Therapeutics Inc

Press Releases

PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotech Investing: How PRVs Can Unlock Major Opportunities

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

PTC Therapeutics to Participate in Upcoming Investor Conferences

Earnings

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies

PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe

DAWN

SWTX

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Nuvalent

Vaxcyte

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Comments

PTC Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga